Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs placebo in men with castration-resistant prostate cancer without baseline bone metastases
2005-005485-37Phase 3Completed
- Sponsor
- Amgen
- Start
- Feb 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Denosumab with Placebo (2 arms). Primary endpoint: Bone metastasis-free survival. Started Feb 2006; status: completed.
02
Drugs
denosumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-005485-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005485-37.